deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03425279

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors

Sponsor: BioAtla, Inc.

Conditions Myxofibrosarcoma Undifferentiated Pleomorphic Sarcoma
Interventions CAB-AXL-ADC PD-1 inhibitor
Updated 24 times since 2018 Last updated: Sep 22, 2025 Started: Feb 15, 2018 Primary completion: Jan 8, 2025 Completion: Jan 8, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03425279, this PHASE1/PHASE2 trial focuses on Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma and remains completed. Sponsored by BioAtla, Inc., it has been updated 24 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Jul 2020 · 13 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Sep 2022 · 11 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Aug 2023 · 9 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Jan 2024 · 3 months · monthly snapshot~Jan 2024 – ~May 2024 · 4 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Jul 2025 · 5 months · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Dec 2025 · 2 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

24 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Oct 2025 — Dec 2025 [monthly]

    Completed PHASE1/PHASE2

    Status: Active Not Recruiting → Completed

  3. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Jul 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  5. Feb 2025 — Jul 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 19 earlier versions

  1. Sep 2024 — Feb 2025 [monthly]

    Recruiting PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jan 2024 — May 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. Oct 2023 — Jan 2024 [monthly]

    Recruiting PHASE1_PHASE2

  6. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE1_PHASE2

  7. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE1_PHASE2

  8. Nov 2022 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  9. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1_PHASE2

  10. Oct 2021 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE1_PHASE2

  12. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jun 2019 — Jul 2020 [monthly]

    Recruiting PHASE1_PHASE2

  14. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

  15. Feb 2019 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  16. Nov 2018 — Feb 2019 [monthly]

    Recruiting PHASE1_PHASE2

  17. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  18. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  19. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Feb 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BioAtla, Inc.
Data source: BioAtla, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Boston, United States , Buffalo, United States , Chicago, United States , Cincinnati, United States , Cleveland, United States , Columbus, United States , Dallas, United States , Denver, United States , Durham, United States and 21 more locations